HMN214

CAS No. 173529-46-9

HMN214( HMN214 | HMN 214 | HMN-214 )

Catalog No. M17370 CAS No. 173529-46-9

HMN-214(IVX214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 43 In Stock
5MG 69 In Stock
10MG 113 In Stock
25MG 207 In Stock
50MG 332 In Stock
100MG 478 In Stock
500MG 1062 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    HMN214
  • Note
    Research use only, not for human use.
  • Brief Description
    HMN-214(IVX214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM.
  • Description
    HMN-214 is an oral prodrug of HMN-176, a stilbene derivative that interferes with the subcellular spatial location of polo-like kinase-1, a serine/threonine kinase that regulates critical mitotic events.(In Vitro):HMN-214 is a prodrug of HMN-176. HMN-176 shows potent activities against 22 human tumor cell lines, with a mean IC50s of 118 nM. HMN-176 (3-300 nM) inhibits luciferase expression driven by the MDR1 promoter in a dose dependent manner in HeLa cells. HMN-176 (30-3000 nM) also dose-dependently suppresses complex formation on the Y-box. HMN-214 (3.3 μM) enhances luciferase expression relative to vehicle control with the 1,4C-1,4Bis polymer (11-fold) and PEI (37-fold) in PC3-PSMA cells. HMN-214 (≥ 3.3 μM) significantly reduces cell proliferation, causes considerable changes in cell morphology in MB49 cells.(In Vivo):HMN-214 (33 mg/kg, p.o.) converts to HMN-176 in rats. HMN-214 has no effect on the conduction velocity and the amplitude of action potentials in the aciatic and tibial nerves. HMN-214 (20 mg/kg, p.o.) exhibits antitumor activity in mice. HMN-214 (10, 20 mg/kg, p.o.) decreases MDR1 mRNA expression in nude mice bearing KB- and KB-A.1.-derived tumors.
  • In Vitro
    HMN-214 is a prodrug of HMN-176. HMN-176 shows potent activities against 22 human tumor cell lines, with a mean IC50s of 118 nM. HMN-176 (3-300 nM) inhibits luciferase expression driven by the MDR1 promoter in a dose dependent manner in HeLa cells. HMN-176 (30-3000 nM) also dose-dependently suppresses complex formation on the Y-box. HMN-214 (3.3 μM) enhances luciferase expression relative to vehicle control with the 1,4C-1,4Bis polymer (11-fold) and PEI (37-fold) in PC3-PSMA cells. HMN-214 (≥ 3.3 μM) significantly reduces cell proliferation, causes considerable changes in cell morphology in MB49 cells.
  • In Vivo
    HMN-214 (33 mg/kg, p.o.) converts to HMN-176 in rats. HMN-214 has no effect on the conduction velocity and the amplitude of action potentials in the aciatic and tibial nerves. HMN-214 (20 mg/kg, p.o.) exhibits antitumor activity in mice. HMN-214 (10, 20 mg/kg, p.o.) decreases MDR1 mRNA expression in nude mice bearing KB- and KB-A.1.-derived tumors.
  • Synonyms
    HMN214 | HMN 214 | HMN-214
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    PLK1
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    173529-46-9
  • Formula Weight
    424.47
  • Molecular Formula
    C22H20N2O5S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 25 mg/mL 58.90 mM;
  • SMILES
    CC(=O)N(c1ccccc1/C=C/c1cc[n+](cc1)[O-])S(=O)(=O)c1ccc(cc1)OC
  • Chemical Name
    (E)-4-(2-(N-((4-methoxyphenyl)sulfonyl)acetamido)styryl)pyridine 1-oxide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Garland LL, et al. Clin Y Res. 2006 Sep 1;12(17):5182-9.
molnova catalog
related products
  • gp120-α4β7 binding i...

    gp120-α4β7 binding inhibitor 11 is an anti-HIV agent. gp120-α4β7 binding inhibitor 11 interferes the binding of HIV associated glycoprotein gp12G with the integrin α4β7 (IC50=1.64nM).

  • BMS-986001

    A thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-2 isolates from treatment-naive individuals with EC50 of 30-81 nM.

  • Saquinavir

    Apotent and selective inhibitor of HIV-1 protease with IC50 of 0.5-6 nM in cell assays.